NYSE:WCN
NYSE:WCNCommercial Services

Assessing Waste Connections (WCN) Valuation After Recent Share Price Weakness

Why Waste Connections stock is drawing fresh attention Waste Connections (WCN) is back on investors’ radar after recent share price weakness, with the stock showing negative returns over the past week, month, past 3 months and year despite positive multi year performance. See our latest analysis for Waste Connections. The recent 6.5% 7 day share price decline and 6.4% year to date share price return have taken some momentum out of Waste Connections, even though the 5 year total shareholder...
NasdaqGM:TTD
NasdaqGM:TTDMedia

OpenAds Publisher Backing Could Be A Game Changer For Trade Desk (TTD)

Earlier this month, The Trade Desk announced that major publishers including AccuWeather, BuzzFeed, the Guardian, Hearst, Newsweek, People Inc., and Ziff Davis are backing its new OpenAds auction environment, which aims to give publishers and sellers a more direct, transparent way to run digital ad auctions. This broad publisher support highlights growing industry demand for higher-integrity programmatic auctions and positions OpenAds as a potential benchmark for transparency across the...
NYSE:PG
NYSE:PGHousehold Products

Procter & Gamble (PG) Valuation Check After Recent Share Price Stability

Procter & Gamble (PG) is back in focus after recent share moves, as investors weigh its consumer staples profile against mixed return figures over different time frames and a current share price of $144.24. See our latest analysis for Procter & Gamble. Recent trading has been steady rather than sharp, with a 7 day share price return of 3.1% on top of a year to date share price return of 1.7%. However, the 1 year total shareholder return of 7.3% and 5 year total shareholder return of 22.4%...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?

In early January 2026, Intellia Therapeutics reported a fatal safety event and Grade 4 liver abnormalities in its Phase 3 MAGNITUDE ATTR-CM trial, prompting the FDA to place both MAGNITUDE and MAGNITUDE-2 studies on clinical hold while the company works with regulators on a path forward for nexiguran ziclumeran (nex-z). This setback for Intellia’s lead in vivo CRISPR program sharply elevates its regulatory and development risk profile, particularly given the company’s reliance on a...
NasdaqCM:SSII
NasdaqCM:SSIIMedical Equipment

Surging 2025 Revenue and New Leadership Could Be A Game Changer For SS Innovations International (SSII)

SS Innovations International recently issued preliminary, unaudited results indicating fourth-quarter 2025 revenue of about US$15.0 million and full-year 2025 revenue of about US$43.0 million, both sharply higher than 2024 levels and driven by increased SSi Mantra surgical robot sales and installations. Alongside this growth, the company expanded its leadership bench by appointing veteran executive Milan Rao as both Chief Financial Officer and Global Chief Operating Officer, underscoring its...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain

If you are wondering whether Teva Pharmaceutical Industries is still reasonably priced after its recent run, this article will walk through what the current share price might be implying about value. Teva's stock last closed at US$32.47, with returns of 1.1% over 7 days, 9.0% over 30 days, 4.9% year to date, 54.8% over 1 year and 194.6% over 3 years. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on Teva as investors...
NasdaqGS:RARE
NasdaqGS:RAREBiotechs

A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Upgraded 2025 Guidance And DTX401 BLA Completion

Ultragenyx Pharmaceutical (RARE) is back in focus after reporting preliminary 2025 revenue guidance of US$672 million to US$674 million, which is above its prior range, alongside completing an FDA BLA submission for gene therapy candidate DTX401. See our latest analysis for Ultragenyx Pharmaceutical. The raised 2025 revenue guidance and DTX401 BLA completion come after a volatile period, with a 7 day share price return of 6.97% but a 30 day share price return of a 33.45% decline, and a 1 year...
NasdaqGS:INTC
NasdaqGS:INTCSemiconductor

Intel (INTC) Valuation After Analyst Upgrades And Growing AI And Foundry Momentum

Intel (INTC) is back in the spotlight after a cluster of analyst upgrades tied to surging AI server CPU demand, tighter 2026 capacity, progress on its 18A foundry ramp, and new Core Ultra Series 3 AI PC chips. See our latest analysis for Intel. Those AI driven headlines have played out in the share price too, with a 27.29% 90 day share price return, a 20.09% year to date share price return and a very large 1 year total shareholder return, suggesting momentum has been building as investors...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Is Sarepta Therapeutics (SRPT) A Potential Opportunity After An 82% One-Year Share Price Decline

For investors considering whether Sarepta Therapeutics is a potential bargain or a value trap at its current share price, this article walks through what the numbers say about the stock. The share price recently closed at US$21.46, with returns of a 4.0% decline over 7 days, a 0.3% decline over 30 days, a 0.7% gain year to date, and declines of 81.9% over 1 year, 83.5% over 3 years, and 77.8% over 5 years. Recent coverage of Sarepta has focused on how the company fits into the high risk,...
NYSE:LII
NYSE:LIIBuilding

Assessing Lennox International (LII) Valuation As Recent Returns Diverge From Discounted Cash Flow Estimates

Why Lennox International Is On Investors’ Radar Today Lennox International (LII) has caught attention after recent share performance, with the stock showing mixed returns across different periods and a last close of US$531 that some investors are reassessing. See our latest analysis for Lennox International. Recent price moves at Lennox International have been relatively steady, with a 4.99% 1 month share price return and a 6.43% year to date share price return. The 1 year total shareholder...
NasdaqGS:COIN
NasdaqGS:COINCapital Markets

Should Coinbase’s Tokenized Stocks and Leverage Push Require Action From Coinbase Global (COIN) Investors?

In recent weeks, Coinbase Global has outlined an ambitious push into tokenized equities, expanded institutional crypto services with Standard Chartered, and prepared a 31-product derivatives platform offering up to 10x leverage on major cryptocurrencies, while simultaneously clashing with U.S. lawmakers over potential limits on stablecoin rewards. This combination of innovation in tokenization and derivatives, deeper institutional integration, and regulatory tension around a key revenue...
NasdaqGS:AAPL
NasdaqGS:AAPLTech

Is It Time To Reassess Apple (AAPL) After Recent Share Price Weakness?

If you are wondering whether Apple stock is still reasonably priced at its current level, this article will help you connect the share price to what the business may be worth using clear valuation checks. Apple shares last closed at US$261.05, with returns of a 0.5% decline over 7 days, a 6.2% decline over 30 days, a 3.7% decline year to date and 12.4% over 1 year, alongside very large 3 year and 5 year gains of 94.9% and 109.8%. These moves are happening as Apple continues to feature...
NYSE:ARES
NYSE:ARESCapital Markets

A Fresh Look At Ares Management (ARES) Valuation After Mixed Recent Share Price Returns

Ares Management (ARES) has drawn fresh attention after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months, while longer term performance remains significantly higher. See our latest analysis for Ares Management. Against a longer backdrop of strong total shareholder return, including a 3 year total shareholder return of 136.01% and 5 year total shareholder return of 330.13%, the recent 1 day share price return of 2.91% decline and softer...
NYSE:LC
NYSE:LCConsumer Finance

Does LendingClub (LC) Still Offer Upside After A 31% One Year Share Price Gain?

If you are wondering whether LendingClub's share price still lines up with its fundamentals, you are not alone. This article focuses squarely on what the current price might imply about value. With the stock at US$20.16 and returns of 0.9% over 7 days, 1.3% over 30 days, 5.4% year to date, 30.7% over 1 year and 99.6% over 3 years, many investors are asking how much of the story is already in the price. Recent attention on LendingClub has been shaped by ongoing discussion around its role in...
NYSE:MRK
NYSE:MRKPharmaceuticals

Assessing Merck (MRK) Valuation After Mixed Short Term Returns And Modest Earnings Multiple

Merck stock reaction and recent return profile Merck (MRK) has drawn investor attention after a stretch of mixed short term performance, with a 0.9% decline over the past day, a 0.6% decline over the past week, and gains over the month and past 3 months. Against this backdrop, the stock’s 1 year total return of 12.7% and 5 year total return of 59.9% sit alongside a value score of 5. This combination prompts a closer look at how its current pricing lines up with its fundamentals. See our...
NasdaqGS:MSFT
NasdaqGS:MSFTSoftware

Does Microsoft’s AI Power Pledge and Retail Push Reshape the Bull Case For Microsoft (MSFT)?

In recent days, Algolia, Hanshow, PayPal, Fiserv and others announced new collaborations with Microsoft, while Microsoft itself unveiled agentic AI retail solutions and a “Community-First AI Infrastructure” plan that commits to covering data center electricity costs, grid upgrades, and higher local utility rates to shield residential customers. Together, these moves signal Microsoft’s attempt to shape both the consumer-facing future of AI shopping and the public policy debate around data...
NasdaqGS:ICFI
NasdaqGS:ICFIProfessional Services

ICF International (ICFI) Valuation After Nearly US$300 Million In New EU Communication Contracts

ICF International (ICFI) recently announced two contracts with European institutions to run public communication campaigns across all 27 EU member states, with a combined ceiling of nearly US$300 million over up to five years. See our latest analysis for ICF International. The new European contracts arrive as ICF International’s share price sits at US$93.05, with a 7-day share price return of 4.88% and a year to date share price return of 9.07%. The 1-year total shareholder return of negative...
NYSE:CIVI
NYSE:CIVIOil and Gas

Assessing Civitas Resources (CIVI) Valuation After Recent Share Price Weakness

Civitas Resources (CIVI) has drawn attention after a stretch of negative returns. The stock is down about 10% over the past month and 7% over the past 3 months, inviting closer scrutiny from investors. See our latest analysis for Civitas Resources. Those short term moves sit within a tougher stretch for holders, with a year to date share price return of a 5.11% decline and a 1 year total shareholder return of a 47.54% decline, even though the 5 year total shareholder return of a 72.84% gain...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

A Look At Fiserv (FISV) Valuation After Recent AI And Clover Expansion News

Recent product news around Fiserv (FISV) has put the stock back on watch, as the company moves to deepen AI capabilities, expand merchant analytics, and widen its Clover payment reach in healthcare settings. See our latest analysis for Fiserv. Even with the AI partnership news and Clover expansion, Fiserv’s share price has been under pressure, with a 90 day share price return showing a 44.88% decline and a 1 year total shareholder return showing a 67.35% decline, suggesting momentum has been...
NYSE:KNTK
NYSE:KNTKOil and Gas

Should Kings Landing Ramp Up and UBS Spotlight Require Action From Kinetik Holdings (KNTK) Investors?

Kinetik Holdings Inc. recently presented at the UBS Global Energy & Utilities Winter Conference in Park City, Utah, following the Kings Landing gas processing project entering full commercial service in New Mexico. The combination of a major infrastructure milestone and increased attention from Wall Street highlights how Kinetik’s growing processing footprint is shaping investor expectations. Next, we’ll examine how the Kings Landing commercial ramp and recent analyst upgrade may influence...
NasdaqCM:NNE
NasdaqCM:NNEElectrical

How Investors May Respond To NANO Nuclear Energy (NNE) South Korea Micro Reactor Localization Deal

NANO Nuclear Energy Inc. recently signed a Memorandum of Understanding with South Korea’s DS Dansuk Co., Ltd. to collaborate on the development, localization, and deployment of its KRONOS MMR and other micro modular reactor systems in the country. This agreement gives NANO Nuclear access to South Korea’s industrial, regulatory, and institutional networks, potentially accelerating its pathway from reactor design to practical deployment across one of the world’s most advanced nuclear...
NasdaqGS:WING
NasdaqGS:WINGHospitality

Wingstop (WING) Valuation Check As Leadership Reshuffle Puts New Focus On Execution

Wingstop (WING) is in focus after reinstating its Chief Operating Officer role, appointing Rajneesh Kapoor to oversee global franchise development and company owned restaurants, along with reassignments affecting two senior executives with planned departures. See our latest analysis for Wingstop. Wingstop’s leadership reshuffle lands after a strong 30 day share price return of 16.86% and a 90 day share price return of 10.14%. The 1 year total shareholder return of 1.25% contrasts with the...
NYSE:WLK
NYSE:WLKChemicals

Is Westlake (WLK) Pricing Reflect Recent Share Rebound Or Stretching Valuation Limits

If you are wondering whether Westlake's current share price still offers value, you are not alone. This article walks through what the numbers are really saying about the stock. Westlake's shares last closed at US$85.00, with returns of 9.8% over the past week, 14.2% over the last month, 14.6% year to date, but a 24.1% decline over the past year and a 20.0% decline over three years, compared with a 7.9% gain over five years. Recent news coverage around Westlake has focused on its position in...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Is Meta Platforms (META) Still Attractively Priced After Its Recent Share Price Pullback

If you are wondering whether Meta Platforms is still reasonably priced after its big run in recent years, this article will walk through what the current share price could imply about value. The stock most recently closed at US$631.09, with a 7 day return of a 4.5% decline, a 30 day return of a 2.0% decline, a year to date return of a 3.0% decline and a 1 year return of 6.5%, while the 3 year return is very large and the 5 year return is 143.4%. Recent headlines around Meta have focused on...